Table 6.
Comparisons of the ratings of ICI and CT in the three patient groups
| ICI patients (N = 53) | CT patients (N = 55) | NoC patients (N = 53) | Mixed ANOVAa | ||||
|---|---|---|---|---|---|---|---|
| ICI | CT | ICI | CT | ICI | CT | ||
| Costs | 8.3 ± 1.9*,+ | 6.3 ± 1.9 | 7.3 ± 2.2 | 7.6 ± 1.9 | 6.5 ± 2.3 | 6.8 ± 2.0 | F (2, 154) = 14.875, p < 0.001 |
| Time required | 5.2 ± 2.2 | 6.5 ± 2.0 | 6.0 ± 2.1 | 7.1 ± 1.7 | 5.6 ± 1.9 | 7.1 ± 1.5 | F (2, 155) = 0.418, p = 0.659 |
| Prospect of success | 8.3 ± 1.8*,+ | 6.1 ± 2.4 | 7.1 ± 1.8 | 7.5 ± 1.7+ | 6.4 ± 1.7* | 5.8 ± 1.7 | F (2, 153) = 16.091, p < 0.001 |
| Minor adverse effects | 4.5 ± 3.1 | 7.5 ± 1.9 | 5.0 ± 2.3 | 7.2 ± 2.3 | 4.5 ± 1.9 | 8.3 ± 1.5 | F (2, 155) = 4.701, p < 0.010 |
| Severe adverse effects | 3.4 ± 2.6* | 6.9 ± 2.4 | 4.4 ± 2.1* | 6.4 ± 2.7 | 4.2 ± 2.0* | 8.1 ± 1.6+ | F (2, 155) = 6.906, p = 0.001 |
| Life-threatening adverse effects | 2.3 ± 2.6* | 5.1 ± 3.0 | 2.8 ± 2.2* | 3.9 ± 2.8 | 2.9 ± 2.0* | 4.9 ± 2.7 | F (2, 155) = 6.167, p = 0.003 |
| This is the future of cancer therapy | 8.3 ± 1.7 | 5.6 ± 2.8 | 7.2 ± 2.5 | 5.9 ± 2.6 | 6.4 ± 2.2 | 4.7 ± 2.3 | F (2, 154) = 2.556, p = 0.081 |
+Rating differs significantly from the two ratings of the other patient groups (post hoc between-subjects, Tukey HSD)
*ICI rating differs significantly from the CT rating (post hoc within-subject, repeated measures ANOVA)
ap < 0.007 is defined as significant (in bold) based on Bonferroni correction for multiple comparisons